ReviewEuropean journal of immunology2015
Inhibitory receptors as targets for cancer immunotherapy.
Review in European journal of immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 2 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes.International journal of cancer · 2019Pooled it
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.PloS one · 2016Pooled it
- Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.Journal of cancer research and clinical oncology · 2021Trial
- From Tregs to tissue remodelling: FOXP3 and IL-35 in the inflammatory landscape of nasal polyps.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Spatiotemporal mapping of CD112 unveils its dichotomous role in T-cell exhaustion and ferroptosis crosstalk in cervical cancer.Cell death & disease · 2026Article
- Article
- Differential T cell reactivation by two PD-L1 nanobodies through blockade alone or blockade with internalization.Scientific reports · 2026Article
- Targeting CB1 and TRPM8 receptors to counteract CD8+ T cell exhaustion.Scientific reports · 2026Article
- A study on the correlation between systemic inflammatory markers in the local tumor immune microenvironment and Porphyromonas gingivalis infection status in patients with oral squamous cell carcinoma.Frontiers in oncology · 2026Article
- Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment.Cancer cell international · 2025Review
- Emerging new immune checkpoint inhibitors in solid tumor immunotherapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Article
- Identification of CWH43 as a novel prognostic biomarker and therapeutic target in clear cell renal cell carcinoma by a multi-omics approach and correlation with autophagy progression.Discover oncology · 2025Article
- Review
- VSTM1/SIRL-1: An Inhibitory Pattern Recognition Receptor Regulating Myeloid Cells.European journal of immunology · 2025Review
- Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis.Scientific reports · 2024Article
- Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption.Nature immunology · 2024Article
- Enhancing immunity againstmBio · 2024Article
- Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Immune Cytolytic Activity and Strategies for Therapeutic Treatment.International journal of molecular sciences · 2024Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Inhibitory receptors expressed on T cells control immune responses while limiting autoimmunity. However, tumors can hijack these "checkpoints" for protection from immune attack. Tumor-specific T cells that exhibit an exhausted, unresponsive phenotype express high levels of inhibitory receptors including CTLA4, PD1, and LAG3, among others. Intratumoral regulatory T cells promote immunosuppression and also express multiple inhibitory receptors. Overcoming this inhibitory receptor-mediated immune tolerance has thus been a major focus of recent cancer immunotherapeutic developments. Here, we review how boosting the host's immune system by blocking inhibitory receptor signaling with antagonistic mAbs restores the capacity of T cells to drive durable antitumor immune responses. Clinical trials targeting the CTLA4 and PD1 pathways have shown durable effects in multiple tumor types. Many combinatorial therapies are currently being investigated with encouraging results that highlight enhanced antitumor immunogenicity and improved patient survival. Finally, we will discuss the ongoing identification and dissection of novel T-cell inhibitory receptor pathways, which could lead to the development of new combinatorial therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.